All News
Adverse Events With Rheum Biologics Rise With Age
Among patients with rheumatic diseases, age and female sex were important factors associated with the development of a first adverse event after initiating biologic treatment, Spanish researchers reported.
Read Article
RheumNow Podcast – Enough Already with Weaning (6.19.20)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Virtual EULAR 2020 Round Up
In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic sclerosis.
Read Article
Day 3 - Top 5 from EULAR 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Read Article
WHO global safety database shows increased risk of DVT & PE with tofacitinib & baricitinib, who were likely to be older with preexisting VTE risk. In EU, TOFA risk for DVT/PE was OR 2.3; BARI risk was OR 3.4. No VTE risk for BARI in US, TOFA 2.0 VTE risk https://t.co/PUBUzfrydn
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is Up! New FDA approvals for secuminumab, canakinumab, risk of GI perforations, tocilizumab in COVID, Weaning DMARDs/Biologics and Blacks with AS. Watch here>> https://t.co/2fTQPJ5iSr Listen to the podcast on Soundcloud>> https://t.co/uPklKQEauE
Dr. John Cush RheumNow ( View Tweet)
African-Americans with Ank Spondylitis have worse disease compared to whites. Study of 10,990 AS patients shows AA to have high frequency of anterior uveitis, hypertension, diabetes, depression, and heart disease and higher ESR and CRP levels. https://t.co/YyLqlM85sD
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb
Dr. John Cush RheumNow ( View Tweet)
#EULAR2020 #op0079 ASAS-MRI group offers updated definition of the structural lesions in SI joints in AxSpA:
-erosion in >=2 consecutive slices or in >=3 SIJ quadrants
- fat lesions w/depth >1cm in >=1SIJ quadrant
are high priority candidates @RheumNow https://t.co/EU1WWqJ4h3
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT 52wk study. Significant improvement in ASAS40, BASDAI50& ASdAS-CRP ID. MRI BME score significantly decreased (-1.68&-1.03 (no LD) vs -0.39 PBO) @RheumNow https://t.co/UX7mkJ8qMJ
Olga Petryna DrPetryna ( View Tweet)
#eular2020 #op0314 5 y drug-free remission (5DFR) is rare in early AxSpA: 17%pts from DESIR cohort reach 5DFR. Shorter disease duration (<1.3y), lower BASDAI&ASAS-CRP & less peripheral involv more likely to achieve DFR. Imaging and biological data did not predict DFR @RheumNow
Olga Petryna DrPetryna ( View Tweet)
New genome wide association study on anterior uveitis. Heritability for uveitis is 0.7, much greater than axSpA. Includes great data on genetic risk scores @ARVOiovs @AberdeenEpi @hteraG_senoJ https://t.co/gsX39YfrbN https://t.co/e8qBpL5xwy
Dr Philip Robinson philipcrobinson ( View Tweet)
Sustained clinical response shown over the 10 yrs of this German study in r-axSpA and nr-axSpA pts treated with ETN. No new safety signals. Abstract #AB0660 #EULAR2020 @RheumNow https://t.co/KCMDyzHaSr https://t.co/yFSTgWqzBQ
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Anti-CD74 IgA antibodies are most sensitive and specific to identify young male axSpA patients, data from @XBaraliakos and others: Abstract FRI0312 #EULAR2020 @RheumNow https://t.co/yrevk8Wsiw https://t.co/kzcje2rRNa
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
ASAS modification of the Berlin algorithm and the duet algorithm for diagnosing axSpA : results from the screening in axSpA for psoriasis, iritis, and colitis cohort: Abstract FRI0298 #EULAR2020 @RheumNow https://t.co/BkG7c2riRb https://t.co/f63MsxWmd3
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https://t.co/Y7sbtJtm3U https://t.co/P9q7uJozZ9
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Interestingly, first line use was the only predictor of improved retention of SEC in axSpA patients in this French study. Poster #THU0386 #EULAR2020 @RheumNow https://t.co/keI9xGWKCL https://t.co/avLtJzaEOc
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
